Cirena, a pioneer in long and ultra-long, high-purity RNA synthesis, has announced its public launch after successfully supplying high-quality long RNA to top academic and pharmaceutical research teams across the US, Europe, and Japan.

 

As CRISPR and prime editing applications advance, researchers increasingly rely on longer guide RNAs to boost editing efficiency and reduce off-target effects. Until now, obtaining long RNA required stitching together shorter oligos, lengthy purification, or waiting months for delivery—delays that have slowed scientific innovation. Cirena eliminates these bottlenecks, producing long RNA rapidly without compromising quality, allowing scientists to iterate faster and achieve more precise outcomes.

 

“As RNA science evolves, researchers are eager to unlock the potential of longer gRNAs for improved editing precision,” said Marv Caruthers, Co-Founder of Cirena. “Cirena enables this exploration by delivering high quality long RNA rapidly, thus eliminating the delays that have historically slowed innovation.”

 

“While many great companies reliably deliver short RNA, producing long RNA without compromising integrity is notoriously difficult,” said John Rinn, LincSwitch CEO. “Cirena proved that they can reliably deliver 150nt RNA with exceptional quality across the U.S., enabling our team to confidently advance experiments without delays.”

 

Cirena’s proprietary technology ensures sequence integrity for demanding CRISPR and functional genomics workflows. Streamlined operations and rapid turnaround times accelerate gRNA, pegRNA, and related designs. 

 

With proven logistics and dependable global delivery, Cirena supports academic, pharmaceutical, and biotech teams working on CRISPR base and prime editing, oncology research, vaccine development, and gene regulation studies.